AUS
NZ
UK
CA
USA
IND
_06_16_2026_04_54_27_535266.jpg)
Highlights
Healthcare leader CSL, tech firm Life360, and medtech giant ResMed are attracting investor attention
Market conditions suggest these stocks are trading below long-term valuation multiples
Each company shows signs of durable growth across global operations and user bases
For those scanning the ASX today 200 for resilient opportunities, three names from healthcare, technology, and medical devices are drawing focus thanks to their global growth prospects and market positioning. These stocks not only form part of the ASX 200 index, but also stand out for their operational scale and recent performance trends.
Below, we explore how each of these ASX-listed companies may fit into a diversified equity portfolio aiming for long-term growth.
CSL (ASX:CSL) – Global Healthcare Backbone
CSL stands among the largest healthcare companies on the ASX with a global footprint across plasma therapies, vaccines, and treatments for chronic conditions such as kidney disease. It consistently invests in scientific innovation and maintains significant R&D expenditure, supporting a pipeline of high-impact treatments.
Shares in CSL have eased from earlier highs, bringing its valuation multiples down below historical averages. This shift has brought renewed attention from market observers, particularly as profit margins show signs of recovery. The company’s positioning in essential global healthcare makes it a steady candidate for investors seeking quality exposure to defensive growth.
Life360 (ASX:360) – Expanding the Digital Safety Footprint
Known for its family tracking and safety mobile app, Life360 has grown from a tech startup to a prominent ASX 200 constituent. With over 80 million active users globally, the company’s growth trajectory is being shaped by ongoing product expansion, strategic monetisation initiatives, and international scale.
The latest performance update reflects solid revenue growth and continued subscriber gains, highlighting traction in core markets. As the platform continues to broaden its service offerings — from location sharing to emergency assistance — Life360 is emerging as a leading name in connected family tech with long-term potential.
ResMed (ASX:RMD) – Breathing Innovation into Sleep Health
ResMed is a global frontrunner in sleep apnoea and respiratory care devices. Despite earlier market concerns about how wellness trends might influence product demand, the company’s recent financial results show resilience through double-digit revenue gains and margin improvements.
Valuation-wise, ResMed currently trades below its decade-long average earnings multiple. Analysts expect its operational strength and the recurring demand for sleep-related products to sustain growth in the coming quarters. With a long-standing reputation in medtech and strong brand recognition, ResMed remains a cornerstone in the respiratory care segment.
